RS50741B - Proces prečišćavanja rekombinantnog hcg - Google Patents

Proces prečišćavanja rekombinantnog hcg

Info

Publication number
RS50741B
RS50741B YUP-602/02A YUP60202A RS50741B RS 50741 B RS50741 B RS 50741B YU P60202 A YUP60202 A YU P60202A RS 50741 B RS50741 B RS 50741B
Authority
RS
Serbia
Prior art keywords
elution
sample
chromatographic column
recombinant hcg
purification
Prior art date
Application number
YUP-602/02A
Other languages
English (en)
Inventor
Gianfranco Paradisi
Mara Rossi
Laura Scaglia
Original Assignee
Laboratoires Serono Sa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa. filed Critical Laboratoires Serono Sa.
Publication of YU60202A publication Critical patent/YU60202A/sh
Publication of RS50741B publication Critical patent/RS50741B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

Postupak za pripremu rekombinantnog hCG, naznačen time, koji ima specifičnu bioaktivnost u rasponu od 23000 - 28000 IJ/mg iz uzorka koji obuhvata sledeće korake:(a) elucija uzorka kroz hromatografsku kolonu od silicijum dioksida(b) elucija uzorka kroz hromatografsku kolonu za jonsku izmenu(c) elucija kroz drugu hromatografsku kolonu za jonsku izmenu(d) elucija uzorka kroz HPLC kolonu reverzne faze (e) primena eluata na hromatografiju ekskluzije,veličine.Prijava sadrži još 6 zavisnih patentnih zahteva.
YUP-602/02A 2000-02-22 2001-01-22 Proces prečišćavanja rekombinantnog hcg RS50741B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00103690 2000-02-22

Publications (2)

Publication Number Publication Date
YU60202A YU60202A (sh) 2005-09-19
RS50741B true RS50741B (sr) 2010-08-31

Family

ID=8167925

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-602/02A RS50741B (sr) 2000-02-22 2001-01-22 Proces prečišćavanja rekombinantnog hcg

Country Status (32)

Country Link
US (2) US7297777B2 (sr)
EP (2) EP1257564B1 (sr)
JP (1) JP4588960B2 (sr)
KR (1) KR100806911B1 (sr)
CN (1) CN100482679C (sr)
AT (1) ATE406378T1 (sr)
AU (2) AU783320B2 (sr)
BG (1) BG65807B1 (sr)
BR (1) BRPI0108556B8 (sr)
CA (1) CA2399020A1 (sr)
CY (1) CY1108460T1 (sr)
CZ (1) CZ303144B6 (sr)
DE (1) DE60135541D1 (sr)
DK (1) DK1257564T3 (sr)
EA (1) EA006605B1 (sr)
EE (1) EE05644B1 (sr)
ES (1) ES2307585T3 (sr)
HK (1) HK1052016A1 (sr)
HR (1) HRP20020650B1 (sr)
HU (2) HU1300063D0 (sr)
IL (2) IL151308A0 (sr)
ME (1) ME00296B (sr)
MX (1) MXPA02007871A (sr)
NO (1) NO328694B1 (sr)
PL (1) PL205149B1 (sr)
PT (1) PT1257564E (sr)
RS (1) RS50741B (sr)
SI (1) SI1257564T1 (sr)
SK (1) SK287146B6 (sr)
UA (2) UA86938C2 (sr)
WO (1) WO2001062773A1 (sr)
ZA (1) ZA200206109B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1257564T3 (da) * 2000-02-22 2008-10-06 Serono Lab Fremgangsmåde til oprensning af rekombinant HCG med en specifik bioaktivitet
WO2006041945A2 (en) * 2004-10-04 2006-04-20 Novetide, Ltd. A counterion exchange process for peptides
CN1958603B (zh) * 2005-11-04 2010-05-05 上海天伟生物制药有限公司 一种人绒毛膜促性腺素的纯化方法
EA200802426A1 (ru) * 2006-07-11 2009-04-28 Коваль, Антон Александрович Применение хорионического или лютеинизирующего гормона для профилактики или лечения возрастного гипогонадизма
CN101397339B (zh) * 2008-09-24 2012-07-25 上海天伟生物制药有限公司 糖蛋白中去除/灭活病毒的方法
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN101792481B (zh) * 2010-03-12 2012-05-30 丽珠医药集团股份有限公司 一种绒毛膜促性腺激素的纯化方法
WO2012120535A2 (en) * 2011-02-03 2012-09-13 Sanzyme Limited A composition comprising highly purified chorionic gonadotropin, it's formulation and uses of the same
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2013102921A2 (en) * 2011-11-17 2013-07-11 Sanzyme Limited Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)
CN103288950A (zh) * 2012-12-28 2013-09-11 青岛九龙生物医药有限公司 改进柱分离工序洗涤液和洗脱液配比去除杂质的方法
CN104101656A (zh) * 2013-04-01 2014-10-15 上海天伟生物制药有限公司 一种促性腺激素的纯度测定方法
US20150065426A1 (en) * 2013-08-27 2015-03-05 Professional Compounding Centers Of America Testosterone Booster Transdermal Compositions
CN105968185A (zh) * 2016-07-20 2016-09-28 宁波人健药业集团股份有限公司 一种绒促性素纯化方法
CN111233999B (zh) * 2020-03-21 2024-02-23 上海浦东明炎生物技术有限公司 一种从人尿中提取人绒毛膜促性腺激素的方法
CN113398251B (zh) * 2021-07-30 2022-08-05 宁波人健药业集团股份有限公司 一种重组人绒毛膜促性腺激素冻干粉针剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0461200T3 (da) * 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1254370B (it) * 1992-05-22 1995-09-14 Sorin Biomedica Spa Procedimento per la purificazione di proteine da sistemi cellulari.
WO1996029095A1 (en) 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
CN1261579C (zh) * 1996-02-20 2006-06-28 应用研究系统Ars控股公司 形成异源二聚体的杂种蛋白质
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
WO1998056806A1 (en) 1997-06-12 1998-12-17 The Regents Of The University Of California A TRANSCRIPTION FACTOR COACTIVATOR PROTEIN, p/CIP
DK0998486T4 (da) * 1997-06-13 2012-05-14 Genentech Inc Proteinoprensning ved kromatografi efterfulgt af filtrering på en ladet fase
US6583109B1 (en) * 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
DK1257564T3 (da) * 2000-02-22 2008-10-06 Serono Lab Fremgangsmåde til oprensning af rekombinant HCG med en specifik bioaktivitet

Also Published As

Publication number Publication date
DK1257564T3 (da) 2008-10-06
EE200200469A (et) 2004-04-15
HRP20020650B1 (en) 2011-02-28
BRPI0108556B8 (pt) 2021-05-25
CY1108460T1 (el) 2014-04-09
EP1257564A1 (en) 2002-11-20
SI1257564T1 (sl) 2008-12-31
NO328694B1 (no) 2010-04-26
CA2399020A1 (en) 2001-08-30
PL205149B1 (pl) 2010-03-31
ATE406378T1 (de) 2008-09-15
IL151308A (en) 2009-11-18
MEP38908A (en) 2011-02-10
CZ303144B6 (cs) 2012-05-02
BRPI0108556B1 (pt) 2015-04-14
EE05644B1 (et) 2013-04-15
MXPA02007871A (es) 2003-02-10
EP1257564B1 (en) 2008-08-27
HU228935B1 (en) 2013-06-28
BG107000A (en) 2003-04-30
AU783320B2 (en) 2005-10-13
NO20023985D0 (no) 2002-08-21
ME00296B (me) 2011-05-10
AU2680401A (en) 2001-09-03
AU2006200059A1 (en) 2006-02-02
UA78488C2 (en) 2007-04-10
HUP0204231A3 (en) 2005-09-28
CN100482679C (zh) 2009-04-29
HUP0204231A2 (hu) 2003-03-28
ES2307585T3 (es) 2008-12-01
HRP20020650A2 (en) 2004-12-31
JP4588960B2 (ja) 2010-12-01
DE60135541D1 (de) 2008-10-09
BG65807B1 (bg) 2009-12-31
HU1300063D0 (hu) 2003-03-28
EA006605B1 (ru) 2006-02-24
HK1052016A1 (en) 2003-08-29
YU60202A (sh) 2005-09-19
KR20030001359A (ko) 2003-01-06
ZA200206109B (en) 2003-07-31
KR100806911B1 (ko) 2008-02-22
PL357508A1 (en) 2004-07-26
WO2001062773A1 (en) 2001-08-30
US20070299001A1 (en) 2007-12-27
SK287146B6 (sk) 2010-01-07
EP1752466A3 (en) 2012-10-10
CN1404485A (zh) 2003-03-19
CZ20022855A3 (cs) 2002-11-13
NO20023985L (no) 2002-08-21
SK12062002A3 (sk) 2002-12-03
US20030104553A1 (en) 2003-06-05
EP1752466A2 (en) 2007-02-14
JP2003524015A (ja) 2003-08-12
BR0108556A (pt) 2003-01-28
EA200200892A1 (ru) 2003-02-27
PT1257564E (pt) 2008-09-10
US7297777B2 (en) 2007-11-20
UA86938C2 (uk) 2009-06-10
IL151308A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
RS50741B (sr) Proces prečišćavanja rekombinantnog hcg
DK1725581T3 (da) Ny assay til adskillelse og kvantificering af hæmagglutinin-antigener
CY1109251T1 (el) Μεθοδος πα τον καθαρισμο της ερυθροποιητινης
ES2112865T3 (es) Anticuerpos igg purificados.
EE200000605A (et) Adenoviiruse efektiivne puhastamine
WO2004024866A3 (en) Protein purification
DE69936920D1 (de) Neue poröse ionenaustauschharze für die festphasenextraktion und chromatographie
SI1308456T1 (sl) Ciscenje protiteles z ionsko izmenjevalno kromatografijo
HRP20020480B1 (en) Process for the purification of pharmacologically active proteins through cationic exchange chromatography
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
WO2002101021A3 (en) Purification of human serum albumin
RS50416B (sr) Prečišćeni lh
WO2005026323A3 (en) Stationary phases and a purification process using the stationary phases
DK1062244T3 (da) Forbedrede fremgangsmåder til fremstilling af faktor VIII proteiner
Liu et al. Isolation and identification of four major impurities in capreomycin sulfate
NO20006181L (no) Ekspresjonsvektor
AU2002314053A1 (en) Scalable inlet liquid distribution system for large scale chromatography columns
Rogers et al. Evaluation of chromatographic methods for drug products containing polar and non-polar molecules using reversed phase, hydrophilic interaction, and ion exchange chromatography
SE9201976D0 (sv) En metod foer att adsorbera proteiner och peptider till hydrofoba zeoliter
Lindner et al. Peptide analysis: zwitterionic chiral ion-exchangers as complementary option to HILIC and to reversed-phase chromatography
WO2003018596A3 (en) Method for removing endotoxins from protein solutions
GB0026809D0 (en) Separation of metals
RU2087151C1 (ru) Способ получения высокочистого инсулина
Workman Jr The 2024 Lifetime Achievement and Emerging Leader in Chromatography Awards
TW200643414A (en) A novel technology for the purity assay of TRODAT-1 raw material